Literature DB >> 17643014

Serodiagnosis of syphilis in a community: an evaluatory study.

P Rajendran1, S P Thyagarajan, N P Pramod, A G Joyee, K G Murugavel, P Balakrishnan, R Hari, L Jeyaseelan, T Kurien.   

Abstract

PURPOSE: To analyse the prevalence of syphilis in the apparently healthy population and to provide data for implementation of the joint STD/HIV control programme, a population based study was undertaken by using 'probability proportional to size' cluster survey method in three randomly chosen districts of Tamil Nadu, India namely Dindigul, Ramnad and Tanjore.
METHODS: Blood samples were collected from adults (n=1873) aged 15-45 years, from the selected households enrolled in this study. The sera were tested parallelly by rapid plasma reagin (RPR) and Treponema pallidum haemagglutination (TPHA) tests. Reactive samples by RPR and/or TPHA were later analysed by fluorescent treponemal antibody absorption (FTA-ABS) test.
RESULTS: The prevalence of syphilis in the community of Tamil Nadu as per RPR positivity was 2.7% (50/1873) as against 0.7% by TPHA (13/1873). FTA-ABS positivity was observed in only 12 out of 48 (25%) RPR/TPHA reactive samples tested. By taking the positivity by two of the three tests, the community prevalence of acute ongoing syphilis in Tamil Nadu was determined as 1.1% (20/1873).
CONCLUSIONS: The results confirmed that no single serological test for syphilis can act as the marker of ongoing acute infection in an apparently healthy population. The study suggests that for specific diagnosis of ongoing syphilis, the FTA-ABS test may be performed along with RPR and TPHA.

Entities:  

Year:  2003        PMID: 17643014

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  1 in total

1.  Letter to the editor: Syphilis seroreactivity: determining the importance during routine screening.

Authors:  Nidhi Singla; Hena Rani; Jagdish Chander
Journal:  Malays J Med Sci       Date:  2012-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.